Imugene Limited, an immuno-oncology biopharmaceutical company, develops mimotopes and small molecule drug candidates in Australia. Its lead product is HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu receptors, which are expressed on the surface of tumors, including gastric, breast, ovarian, and pancreatic cancers. The company's HER-Vaxx has completed a Phase I clinical trial to treat breast cancer, as well as in Phase Ib/II study for gastric cancer. It has an agreement with the Baker IDI Heart & Diabetes Institute to research, develop, and commercialize a portfolio of small molecule arginine modulators for oncology. The company is based in Carlton, Australia.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61 3 9824 5254
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.13 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Imugene (ASX:IMU) Frequently Asked Questions
What is Imugene's stock symbol?
Imugene trades on the ASX under the ticker symbol "IMU."
Has Imugene been receiving favorable news coverage?
Media headlines about IMU stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Imugene earned a media sentiment score of 0.6 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Imugene.
Who are some of Imugene's key competitors?
Some companies that are related to Imugene include ProMetic Life Sciences (PLI), Rafael (RFL), Pfenex (PFNX), Resverlogix (RVX), CEL-SCI (CVM), 22nd Century Group (XXII), Neuren Pharmaceuticals (NEU), Horizon Discovery Group (HZD), Emblem (EMC), Monash IVF Group (MVF), Silence Therapeutics (SLN), Botanix Pharmaceuticals (BOT), Acasti Pharma (ACST), Enochian Biosciences (ENOB) and Exicure (XCUR).
What other stocks do shareholders of Imugene own?
Who are Imugene's key executives?
Imugene's management team includes the folowing people:
- Mr. Paul Edward Alexander Hopper, Exec. Chairman (Age 63)
- Ms. Leslie Chong, CEO, MD & Exec. Director
- Dr. Nicholas J. Ede, Chief Technology Officer
- Mr. Phillip Allen Hains, CFO & Joint Company Sec. (Age 60)
- Dr. Mark T. Marino, Chief Medical Officer (Age 59)
What is Imugene's stock price today?
One share of IMU stock can currently be purchased for approximately A$0.02.
How big of a company is Imugene?
What is Imugene's official website?
How can I contact Imugene?
The company can be reached via phone at 61 3 9824 5254.
MarketBeat Community Rating for Imugene (ASX IMU)
MarketBeat's community ratings are surveys of what our community members think about Imugene and other stocks. Vote "Outperform" if you believe IMU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMU will underperform the S&P 500 over the long term. You may vote once every thirty days.
